Swedish Orphan Biovitrum AB today announces that Geoffrey McDonough will leave Sobi on 1 July 2017, and that a search for a new Chief Executive Officer has been initiated to identify his successor.
“Geoffrey McDonough has created remarkable value in his term as CEO. Under his leadership Sobi has become a prominent rare disease biotech company with a vibrant and growing commercial portfolio and significant growth potential ahead”, says Håkan Björklund, Chairman of the Board of Sobi, “Given the increasing demand and focus of our business in Europe, the Board has decided that Sobi needs more continuous presence in Stockholm than Geoffrey can sustain given his current location in Boston.”
“Sobi stands today on the platform of a strong and unique rare disease position supported by several years of strong financial results”, says Geoffrey McDonough, CEO and President of Sobi, “The Company is entering a period of unprecedented growth and opportunity that will benefit from local leadership.”
The company will host an investor and analyst conference call on 9 January at 12:30 pm CET, where Geoffrey McDonough, CEO and Håkan Björklund, Chairman of the Board, will make a brief statement and will be available for questions.
Source: Sobi
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
